Back to Search
AMAN BUZDAR, M.D.
M.D.
Medical Oncology Physician
NPI: 1568568749IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
E4811(TX)
Education
OTHER
Class of 1967
Research & Publications (20)
Medical oncology: Endocrine-therapy-related symptoms and breast cancer.
PMID 19483735·Nat Rev Clin Oncol·2009
8-other
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
PMID 19150946·Ann Oncol·2009
6-review
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.
PMID 18072256·Cancer·2008
8-other
Clinical experience with epothilones in patients with breast cancer.
PMID 18637402·Clin Breast Cancer·2008
6-review
Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
PMID 19137123·Drugs Today (Barc)·2008
6-review
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
PMID 18072254·Cancer·2008
8-other
Preoperative chemotherapy treatment of breast cancer--a review.
PMID 17941030·Cancer·2007
4-observational
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
PMID 17200359·Clin Cancer Res·2007
3-trial
Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
PMID 16912252·Ann Pharmacother·2006
4-observational
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
PMID 16467122·Clin Cancer Res·2006
2-rct
Anastrozole for breast cancer: recent advances and ongoing challenges.
PMID 16761927·Expert Rev Anticancer Ther·2006
6-review
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
PMID 16804925·Cancer·2006
8-other
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
PMID 16870082·Curr Med Res Opin·2006
1-meta
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
PMID 15738535·J Clin Oncol·2005
3-trial
Current developments in hormonal therapy of breast cancer.
PMID 15347432·Clin Breast Cancer·2004
6-review
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
PMID 15347433·Clin Breast Cancer·2004
4-observational
Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
PMID 15538548·Drugs Today (Barc)·2004
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1568568749
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 59
- Publications
- 20
Are you this provider?
Claim Your Profile